Clear Search sequence regions


  • antitumor (2)
  • b cell lymphoma (11)
  • BCR (1)
  • c cbl (2)
  • cancers (1)
  • CD28 (1)
  • diseases and (1)
  • IL 2 (1)
  • lymphocytes b (2)
  • mice (2)
  • signal (2)
  • t lymphocytes (5)
  • TCR (1)
  • Sizes of these terms reflect their relevance to your search.

    Casitas B cell lymphoma-b (Cbl-b) is a vital negative regulator of TCR and BCR signaling pathways, playing a significant role in setting an appropriate threshold for the activation of T cells and controlling the tolerance of peripheral T cells via a variety of mechanisms. Overexpression of Cbl-b leads to immune hyporesponsiveness of T cells. Conversely, the deficiency of Cbl-b in T cells results in markedly increased production of IL-2, even in the lack of CD28 costimulation in vitro. And Cbl-b-/- mice spontaneously reject multifarious cancers. Therefore, Cbl-b may be associated with immune-mediated diseases, and blocking Cbl-b could be considered as a new antitumor immunotherapy strategy. In this review, the possible regulatory mechanisms and biological potential of Cbl-b for antitumor immunotherapy are summarized. Besides, the potential roles of Cbl-b in immune-mediated diseases are comprehensively discussed, with emphasis on Cbl-b immune-oncology agents in the preclinical stage and clinical trials.

    Citation

    Lixin Zhou, Jiamei Yang, Kuojun Zhang, Tianyu Wang, Sheng Jiang, Xiangyu Zhang. Rising Star in Immunotherapy: Development and Therapeutic Potential of Small-Molecule Inhibitors Targeting Casitas B Cell Lymphoma-b (Cbl-b). Journal of medicinal chemistry. 2024 Jan 25;67(2):816-837

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 38181380

    View Full Text